165 related articles for article (PubMed ID: 17167543)
1. The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain.
Morrison AA; Venables JP; Dellaire G; Ladomery MR
Biochem Cell Biol; 2006 Oct; 84(5):789-98. PubMed ID: 17167543
[TBL] [Abstract][Full Text] [Related]
2. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.
Ladomery M; Sommerville J; Woolner S; Slight J; Hastie N
J Cell Sci; 2003 Apr; 116(Pt 8):1539-49. PubMed ID: 12640038
[TBL] [Abstract][Full Text] [Related]
3. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
4. Kinetic behaviour of WT 1's zinc finger domain in binding to the alpha-actinin-1 mRNA.
Nurmemmedov E; Yengo RK; Ladomery MR; Thunnissen MM
Arch Biochem Biophys; 2010 May; 497(1-2):21-7. PubMed ID: 20193655
[TBL] [Abstract][Full Text] [Related]
5. New insights into DNA-binding behavior of Wilms tumor protein (WT1)--a dual study.
Nurmemmedov E; Yengo RK; Uysal H; Karlsson R; Thunnissen MM
Biophys Chem; 2009 Dec; 145(2-3):116-25. PubMed ID: 19853363
[TBL] [Abstract][Full Text] [Related]
6. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
7. A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system.
Wagner N; Wagner KD; Hammes A; Kirschner KM; Vidal VP; Schedl A; Scholz H
Development; 2005 Mar; 132(6):1327-36. PubMed ID: 15716344
[TBL] [Abstract][Full Text] [Related]
8. The ratio of +/-KTS splice variants of the Wilms' tumour suppressor protein WT1 mRNA is determined by an intronic enhancer.
Yang C; Romaniuk PJ
Biochem Cell Biol; 2008 Aug; 86(4):312-21. PubMed ID: 18756326
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
10. WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo.
Markus MA; Heinrich B; Raitskin O; Adams DJ; Mangs H; Goy C; Ladomery M; Sperling R; Stamm S; Morris BJ
Exp Cell Res; 2006 Oct; 312(17):3379-88. PubMed ID: 16934801
[TBL] [Abstract][Full Text] [Related]
11. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
[TBL] [Abstract][Full Text] [Related]
12. RNA Binding by the KTS Splice Variants of Wilms' Tumor Suppressor Protein WT1.
Nishikawa T; Wojciak JM; Dyson HJ; Wright PE
Biochemistry; 2020 Oct; 59(40):3889-3901. PubMed ID: 32955251
[TBL] [Abstract][Full Text] [Related]
13. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways.
Wang ZY; Qiu QQ; Huang J; Gurrieri M; Deuel TF
Oncogene; 1995 Feb; 10(3):415-22. PubMed ID: 7845666
[TBL] [Abstract][Full Text] [Related]
14. The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties.
Kim J; Lee K; Pelletier J
Oncogene; 1998 Apr; 16(15):1973-9. PubMed ID: 9591781
[TBL] [Abstract][Full Text] [Related]
15. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
[TBL] [Abstract][Full Text] [Related]
17. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
18. Distinct global binding patterns of the Wilms tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells.
Ullmark T; Järvstråt L; Sandén C; Montano G; Jernmark-Nilsson H; Lilljebjörn H; Lennartsson A; Fioretos T; Drott K; Vidovic K; Nilsson B; Gullberg U
Haematologica; 2017 Feb; 102(2):336-345. PubMed ID: 27612989
[TBL] [Abstract][Full Text] [Related]
19. DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and -KTS isoforms-From initial observations to recent global genomic analyses.
Ullmark T; Montano G; Gullberg U
Eur J Haematol; 2018 Mar; 100(3):229-240. PubMed ID: 29240258
[TBL] [Abstract][Full Text] [Related]
20. Presence of WT1 in nuclear messenger RNP particles in the human acute myeloid leukemia cell lines HL60 and K562.
Morrison AA; Ladomery MR
Cancer Lett; 2006 Nov; 244(1):136-41. PubMed ID: 16457949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
